1. Home
  2. PRKS vs SNDX Comparison

PRKS vs SNDX Comparison

Compare PRKS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Parks & Resorts Inc.

PRKS

United Parks & Resorts Inc.

HOLD

Current Price

$35.17

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$23.93

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRKS
SNDX
Founded
1959
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
PRKS
SNDX
Price
$35.17
$23.93
Analyst Decision
Buy
Strong Buy
Analyst Count
10
13
Target Price
$47.50
$38.69
AVG Volume (30 Days)
944.9K
1.3M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
3.06
N/A
Revenue
$1,263,324,000.00
$172,352,000.00
Revenue This Year
$3.64
$106.95
Revenue Next Year
$3.13
$40.94
P/E Ratio
$11.79
N/A
Revenue Growth
N/A
627.84
52 Week Low
$28.77
$8.59
52 Week High
$56.95
$25.59

Technical Indicators

Market Signals
Indicator
PRKS
SNDX
Relative Strength Index (RSI) 53.08 50.08
Support Level $34.31 $22.40
Resistance Level $37.12 $25.43
Average True Range (ATR) 1.55 1.07
MACD 0.22 -0.14
Stochastic Oscillator 57.70 29.82

Price Performance

Historical Comparison
PRKS
SNDX

About PRKS United Parks & Resorts Inc.

United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: